The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Hi TGTBT, I believe the consolidation was 50/1 administered back in 2017. Since trading only on NASDAQ 8 x ordinary shares represents 1 ADS, hope this helps
Hi all, I’m reaching out for some pointers to who you used to convert the share certificates to ADS. I’ve had limited time to deal with the situation but every broker I’ve tried cannot fulfil the transaction, mainly due to restricted services. Any advice would be welcome.
Morning all, newly invested into this today after a bit of deliberation, don’t normally post but thought I would share that mine was showing as a sell, 47961 shares
Good luck
Better late than never as they say :)
globenewswire.com Verona Pharma Provides Clinical Development Update Verona Pharma plc LONDON, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces updated projections, bringing forward the timing for top-line data readouts from its ongoing clinical trials in chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). Phase 2b clinical trial of nebulized RPL554 for COPD Maintenance Treatment: The Company anticipates reporting top-line data from its Phase 2b trial early in the second quarter of 2018 (previously mid-2018). The four-week, double-blind, placebo-controlled, parallel group Phase 2b study enrolled approximately 400 patients with moderate-to-severe COPD at a number of sites across Europe and is investigating the efficacy, safety, and dose-response of nebulized RPL554 as a maintenance treatment for COPD. Phase 2a pharmacokinetic (PK) and pharmacodynamic (PD) clinical trial of RPL554 for CF: The Company anticipates reporting top-line data from its Phase 2a trial in late first quarter of 2018 (previously first half of 2018). The double-blind, placebo-controlled, cross-over Phase 2a study is evaluating the PK and PD profile and tolerability of single nebulized dose of RPL554 in 10 patients with CF, as well as the effect on lung function in such patients. “We are pleased to be making excellent progress in these important studies,” said Jan-Anders Karlsson, PhD, CEO of Verona Pharma. “We have completed the clinical phase of both studies ahead of schedule and now look forward to reporting top-line data sooner than our previous guidance.” RPL554 is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 designed to have anti-inflammatory as well as bronchodilator properties, and is currently in development for the maintenance treatment of COPD patients and for the treatment of patients with CF. In pre-clinical studies, RPL554 has been observed to stimulate the CF transmembrane conductance regulator, a protein whose mutation results in dysfunctional ion channels in epithelial cells, leading to CF. Based on available data, RPL554 has the potential to enhance mucociliary clearance (reduce phlegm in the airways), reduce airway obstruction and inhibit inflammation. About Verona Pharma plc Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statisticall